Opinion

Video

EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.

Video content above is prompted by the following:

  • Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
  • Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Related Videos
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Alfred L. Garfall, MD, an expert on multiple myeloma
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
CH LogoCenter for Biosimilars Logo